Indivior PLC, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders. The company is headquartered in North Chesterfield, Virginia.
| Revenue (TTM) | $1.29B |
| Gross Profit (TTM) | $1.10B |
| EBITDA | $475.00M |
| Operating Margin | 46.10% |
| Return on Equity | 12.20% |
| Return on Assets | 22.70% |
| Revenue/Share (TTM) | $10.32 |
| Book Value | $-1.18 |
| Price-to-Book | 145.25 |
| Price-to-Sales (TTM) | 3.44 |
| EV/Revenue | 3.697 |
| EV/EBITDA | 13.47 |
| Quarterly Earnings Growth (YoY) | 82.00% |
| Quarterly Revenue Growth (YoY) | 19.20% |
| Shares Outstanding | $118.20M |
| Float | $110.12M |
| % Insiders | 1.43% |
| % Institutions | 106.78% |
Volatility is currently contracting